| sess_SDA-2026-04-07- | The study shows trehalose causes lysosomal membrane permeabilization (LMP) that | 0.61 | 7 | 4 | completed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062150-a6cc7467 |
| target_debate_target | Should NR3C1 (Glucocorticoid receptor) be prioritized as a therapeutic target fo | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should MMP9 (Matrix metalloproteinase-9) be prioritized as a therapeutic target | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| sess_SDA-2026-04-07- | While SPP1 absence prevents synaptic loss, it's unclear whether this represents | 0.69 | 7 | 4 | completed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062118-2cdbb0dd |
| target_debate_target | Should FKBP5 (FKBP prolyl isomerase 5) be prioritized as a therapeutic target fo | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| sess_SDA-2026-04-07- | The study shows that G3BP1 ubiquitination inhibits LLPS in vitro, but the molecu | 0.79 | 7 | 4 | completed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041423-2d1db50c |
| target_debate_target | Should BDNF (Brain Derived Neurotrophic Factor) be prioritized as a therapeutic | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should C1Q (Complement C1q) be prioritized as a therapeutic target for neurodege | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| sess_SDA-2026-04-07- | While the study establishes P2RY12's role in VSMC foam cell formation in atheros | 0.62 | 7 | 4 | completed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041434-d7920f3b |
| target_debate_target | Should CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1) be prioritized a | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should TFR1 (Transferrin receptor protein 1) be prioritized as a therapeutic tar | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should TGM2 (Protein-glutamine gamma-glutamyltransferase 2) be prioritized as a | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| sess_SDA-2026-04-07- | While the abstract identifies AQP4 as a 'potential and promising target' and men | 0.76 | 7 | 4 | completed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041445-7e1dc0b2 |
| target_debate_target | Should SIRT6 (Sirtuin-6) be prioritized as a therapeutic target for neurodegener | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should CX3CR1 (C-X3-C Motif Chemokine Receptor 1) be prioritized as a therapeuti | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| sess_SDA-2026-04-07- | The circadian hypothesis assumes metabolic switching drives microglial priming, | 0.66 | 7 | 4 | completed | 2026-04-21 | SDA-2026-04-07-gap-debate-20260406-062033-839c3e2a |
| target_debate_target | Should LOX (Lysyl oxidase) be prioritized as a therapeutic target for neurodegen | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| sess_SDA-2026-04-07- | The debate identified temporal specificity as a critical weakness - when exactly | 0.68 | 7 | 4 | completed | 2026-04-21 | SDA-2026-04-07-gap-debate-20260406-062039-7ef9980b |
| target_debate_target | Should P2RY12 (P2Y purinoreceptor 12) be prioritized as a therapeutic target for | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should HCRTR2 (Hypocretin Receptor 2) be prioritized as a therapeutic target for | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| sess_SDA-2026-04-07- | While the study establishes TDP-43 triggers mtDNA release via mPTP to activate c | 0.73 | 7 | 4 | completed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062141-611cf046 |
| target_debate_target | Should FCGRT (Fc fragment of IgG receptor and transporter) be prioritized as a t | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should HCRTR1 (Hypocretin Receptor 1) be prioritized as a therapeutic target for | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| sess_SDA-2026-04-07- | The abstract identifies APOE4 association with increased TDP-43 pathology but th | 0.61 | 7 | 4 | completed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-062202-c8c5a9a1 |
| target_debate_target | Should SNCA (Synuclein alpha) be prioritized as a therapeutic target for neurode | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| sess_SDA-2026-04-07- | While the study identifies G3BP1 as a central node triggering phase separation, | 0.76 | 7 | 4 | completed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041428-53b81741 |
| target_debate_target | Should ULK1 (Unc-51 like autophagy activating kinase 1) be prioritized as a ther | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should ADRA2A (Alpha-2A adrenergic receptor) be prioritized as a therapeutic tar | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should HSPA1A (Heat Shock Protein Family A Member 1A) be prioritized as a therap | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should SLC7A11 (Cystine/glutamate transporter) be prioritized as a therapeutic t | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should ADORA2A (Adenosine A2A receptor) be prioritized as a therapeutic target f | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should APOE (Apolipoprotein E) be prioritized as a therapeutic target for neurod | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should CGAS (Cyclic GMP-AMP synthase) be prioritized as a therapeutic target for | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should TREM2 (Triggering receptor expressed on myeloid cells 2) be prioritized a | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should PDGFRB (Platelet-derived growth factor receptor beta) be prioritized as a | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1) be priorit | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should GLP1R (Glucagon-like peptide-1 receptor) be prioritized as a therapeutic | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should G3BP1 (Ras GTPase-activating protein-binding protein 1) be prioritized as | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should NLRP3 (NACHT, LRR and PYD domains-containing protein 3) be prioritized as | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| sess_SDA-2026-04-07- | The study shows P2RY12 regulates VSMC foam cell formation but doesn't explain wh | 0.66 | 7 | 4 | completed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041434-a4d6154a |
| target_debate_target | Should MTNR1B (Melatonin receptor 1B) be prioritized as a therapeutic target for | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| sess_SDA-2026-04-07- | The abstract describes IBA1 low/negative microglia in individuals with liver dis | 0.76 | 7 | 4 | completed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041439-306c2cdb |
| target_debate_target | Should P2RY1 (P2Y purinoreceptor 1) be prioritized as a therapeutic target for n | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| sess_SDA-2026-04-07- | The abstract states that AQP4 'is part of the pathogenesis' of CNS disorders and | 0.76 | 7 | 4 | completed | 2026-04-21 | SDA-2026-04-07-gap-pubmed-20260406-041445-ce0abc1e |
| target_debate_target | Should IL1B (Interleukin-1 beta) be prioritized as a therapeutic target for neur | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| sess_SDA-2026-04-07- | The debate raised this developmental hypothesis but couldn't resolve the mechani | 0.71 | 7 | 4 | completed | 2026-04-21 | SDA-2026-04-07-gap-debate-20260406-062045-56983337 |
| target_debate_target | Should TH (Tyrosine hydroxylase) be prioritized as a therapeutic target for neur | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| sess_SDA-2026-04-07- | The debate considered multiple propagation routes (synaptic, extracellular vesic | 0.66 | 6 | 4 | completed | 2026-04-21 | SDA-2026-04-07-gap-debate-20260406-062052-946439a8 |
| target_debate_target | Should PARP1 (Poly [ADP-ribose] polymerase 1) be prioritized as a therapeutic ta | 0.50 | 0 | 4 | completed | 2026-04-21 | |
| target_debate_target | Should C3 (Complement C3) be prioritized as a therapeutic target for neurodegene | 0.50 | 0 | 4 | completed | 2026-04-21 | |